Topical formulation of arginine-rich cyclic antimicrobial peptides

ABSTRACT

The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 13/592,246, filed Aug. 22, 2012, which is a divisional of U.S.patent application Ser. No. 12/158,945, filed Aug. 15, 2008, which isthe US national phase entry of PCT patent application no.PCT/GB2006/04890, filed Dec. 21, 2006, which claims priority to U.S.provisional application No. 60/776,505, filed Feb. 24, 2006 and UnitedKingdom patent application no. 0526120.1, filed Dec. 22, 2005.

FIELD OF THE INVENTION

The present invention relates to cyclic cationic peptides and their usein the treatment of microbial infections.

BACKGROUND TO THE INVENTION

Antimicrobial peptides (AMP) form the cornerstone of eukaryotic immunityand provide a first line of defense against breach of the skin andmucosal surfaces by micro-organisms. Examples of natural AMP include thedefensin and cathelicidin families of peptides. These AMP areheterogeneous in length, sequence and structure, but common to most istheir small size, net cationic charge and amphipathic structure. Small,cationic antimicrobial peptides have also been isolated from manybacteria, fungi, plants, invertebrates and vertebrates and wouldtherefore appear also to play a role in prokaryotic defenses.

Natural AMP exhibit broad-spectrum activity against Gram-positive andGram-negative bacteria, yeasts, fungi and enveloped viruses. Microbialpathogens do not seem to acquire resistance to these cationic peptidesand as such, AMP have been conserved as a vital innate immune hostdefense molecules through millennia of evolution. It is not surprisingtherefore that AMP have been implicated as potential targets fortherapeutics for a wide range of infections. However, the fact that theyare technically challenging and costly to produce in recombinant systemsand have potent chemotactic and inflammatory biological functions rulesout natural AMP forms for use as therapeutics.

In our co-pending application we have shown that linear peptides rich incertain basic residues such as lysine or arginine possess antimicrobialactivity, and, in particular, anti-fungal activity. There remains,however, a need for further agents that can be used in the treatment orprevention of microbial infections.

STATEMENTS OF THE INVENTION

According to a first aspect of the invention, there is provided apeptide comprising from 2 to about 200 D and/or L amino acids, which maybe the same or different, wherein the amino acids are selected from thegroup consisting of hydrophobic amino acids and/or cationic amino acids,and wherein the peptide is cyclic. The cyclic peptide may comprise 3 toabout 100 D and/or L amino acids, for example 3 to 50 amino acids Dand/or L amino acids including 4 to about 50 D and/or L-amino acids.

The peptides of the invention are useful in the treatment or preventionof microbial infections.

The cyclic peptides of the invention are desirable as a therapeutic asthey are highly effective, proteolytically stable, substantially saltinsensitive, not hepatotoxic, non-haemolytic and easy to synthesize.

The cationic charge of the peptides of the invention is believed tofacilitate the association of the peptide with the polar head-groups ofmicrobial membranes. Stabilization of the charged groups in a more denseconfirmation by cyclisation is believed to enhance this attractionthereby increasing the antimicrobial potency of the peptides.

In a further aspect of the invention there is provided a peptidecomprising amino acids according to the formula I:((X)_(l)(Y)_(m))_(n)  (I)wherein l and m are integers from 0 to 10 such that both l and m are not0; n is an integer from 1 to 10; X and Y, which may be the same ordifferent, are an amino acid selected from the group consisting ofhydrophobic amino acids and/or cationic amino acids and wherein thepeptide is cyclic, for use as a pharmaceutical.

The peptide may comprise from 2 to 50 amino acids, for example 3, 4, 5,6, or 7 up to 50 amino acids, including 3, 4, 5, 6, or 7 up to 10, 15,20, 25, 30, 35, 40, 45 or 50 amino acids.

In a preferred aspect of the invention the peptide comprises 2 to 15amino acids, for example 3 to 15 amino acids. Preferably still thepeptide comprises 5 to 13 amino acids. Yet further preferred arepeptides comprising 3 to 7 amino acids, for example 7 amino acids.

As known to the skilled person, amino acids can be placed into differentclasses depending primarily upon the chemical and physical properties ofthe amino acid side chain. For example, some amino acids are generallyconsidered to be hydrophilic or polar amino acids and others areconsidered to be hydrophobic or non-polar amino acids. Hydrophobic aminoacid may be selected from the group of hydrophobic amino acidsconsisting of glycine, leucine phenylalanine, proline, alanine,tryptophan, valine, isoleucine, methionine, tyrosine and threonine;cationic amino acids may be selected from the group consisting ofornithine, histidine, arginine and lysine. As used herein, the terms“hydrophobic” and “cationic” may refer to amino acids having ahydrophobicity that is greater than or equal to −1.10 and/or a netcharge that is greater than or equal to 0 as described in Fauchere andPliska Eur. J. Med Chem. 10:39 (1983). A hydrophobic or non-polar aminoacid may also refer to an amino acid having a side chain that isuncharged at physiological pH, is not polar and that is generallyrepelled by aqueous solution. The amino acids may be naturally occurringor synthetic.

In a preferred aspect of the invention, X and/or Y are cationic aminoacids selected from the group consisting of histidine, ornithinearginine and lysine. Preferably still X and/or Y are arginine or lysine.

X and/or Y may optical isomers of a hydrophobic or cationic amino acidas defined herein for example D or L-amino acids. Preferably X and/or Yare D-amino acids.

In a preferred aspect of the invention, the peptide of formula (I)consists of at least 90%, for example at least 95% such as 97-99% oreven 100%, of D-amino acids.

In a preferred aspect of the invention, the peptide of formula (I)consists of at least 90%, for example at least 95% such as 97-99% oreven 100%, of L-amino acids.

The invention also includes known isomers (structural, stereo-,conformational and configurational), peptidomimetics, structuralanalogues of the above amino acids, and those modified either naturally(e.g. post-translational modification) or chemically, including, but notexclusively, phosphorylation, glycosylation, sulfonylation and/orhydroxylation.

In general, the peptide of the invention does not include the aminoacids aspartic acid, glutamic acid, asparagine, glutamine or serine, butcertain peptides of the invention may have activity even though theseamino acids are present.

In a further preferred aspect, X and Y are the same. Preferably still Xand Y are the same and are lysine or arginine.

In the peptide of formula (I) l and m may be 1, 2, 3, 4, 5, 6, 7, 8, 9or 10 and n may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

In the peptide of formula (I) l may be 1, n may be 1 and m may bebetween 4 and 9, for example, m may be 3, 4, 5, 6, 7, 8 or 9.

In the peptide of formula (I) l, n and/or m may be between 1 and 5, forexample, 1, 2, 3, 4 or 5.

In the peptide of formula (I) l and m may be an integer between 0 and 7and n may be an integer between 1 and 10.

In the peptide of formula (I) l and m may be 0, 1 or 2 and n may be aninteger between 1 and 10.

In the peptide of formula (I) X and Y may be the same, l may be 0, m maybe 1 and n may be 3, 4, 5, 6, 7, 8, 9 or 10.

In the peptide of formula (I) X and Y may be the same, l and m may be 1and n may be 2, 3, 4 or 5.

In the peptide of formula (I) X and Y may be the same, l may be 1, m maybe 2 and n may be 1, 2, 3 or 4.

In the peptide of formula (I) X and Y may be the same, l and m may be 2and n may be 1, 2, 3 or 4.

In a further aspect of the invention there is provided a cyclic peptidecomprising amino acids according to the formula II:(X)_(n)  (II)wherein X and n are as described herein. Preferably X is lysine,arginine or ornithine. Preferably n is an integer between 3 and 15.

In one embodiment of the invention X is arginine.

In an alternative embodiment of the invention X is lysine.

In a yet alternative embodiment of the invention X is ornithine.

The peptides of the invention may comprise one or more cysteineresidues, for example up to 6 cysteine residues, such as 1, 2, 3, 4, 5or 6 cysteine residues.

In addition, the amino acid sequence of the peptide can be modified soas to result in a peptide variant that includes the substitution of atleast one amino acid residue in the peptide for another amino acidresidue, including substitutions that utilize the D rather than L form.

One or more of the residues of the peptide can be exchanged for anotherto alter, enhance or preserve the biological activity of the peptide.Such a variant can have, for example, at least about 10% of thebiological activity of the corresponding non-variant peptide.Conservative amino acids are often utilized, i.e. substitutions of aminoacids with similar chemical and physical properties as described above.Hence, for example, conservative amino acid substitutions may involveexchanging lysine for arginine, ornithine or histidine; or exchangingarginine for lysine or isoleucine, ornithine for histidine; orexchanging one hydrophobic amino acid for another. After thesubstitutions are introduced, the variants are screened for biologicalactivity.

The term “peptide” as used herein means, in general terms, a pluralityof amino acid residues joined together by peptide bonds. It is usedinterchangeably and means the same as polypeptide and protein.

In one embodiment of the invention, the cyclic peptide is selected fromthe group consisting of:

K-K-K-K-K-K-K; and

R-R-R-R-R-R-R.

The peptides of the invention generally are synthetic peptides. Thepeptides may be isolated, purified peptides or variants thereof, whichcan be synthesized in vitro, for example, by a solid phase peptidesynthetic method, by enzyme catalyzed peptide synthesis or with the aidof recombinant DNA technology.

In a further aspect of the invention there is provided a process for thepreparation of a peptide according to the invention, the processcomprising cyclizing a peptide of formula (I) or (II) by reaction of thepeptide with a coupling agent.

The coupling agent may be any agent capable of forming a peptide bondbetween the two terminal (C and N terminal) amino acid residues of thepeptide when in its linear form, for example, between two amino acidbackbones or side chains. The choice of coupling agent can influence theefficiency of coupling and hence the yield of the cyclic peptide.Examples of coupling agents useful in the process of the invention isshown in Table 1 although the skilled person will be aware of otherknown coupling agents that are also useful in the invention. Preferablythe coupling agent isHATU-O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate.

Preferably the reaction between the peptide and the coupling agent takesplace in the presence of a base. The base may include, but is notlimited to, n-methylmorpholine (NMM) or diisopropyl-ethylamine (DIEA).Preferably the reaction takes place at alkaline pH, for example betweenpH 8.5-9. The peptide may be modified to include a protecting groupprior to its reaction with the coupling agent. Protecting groups mayinclude Pbf (2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl), tBu(t-butyl-ether), Mtr (methoxytrimethyl-benzene sulfonyl), Pmc(2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride), Mbh(4,4-dimethyloxybenzylhydride), Tmob (2,4,6-trimethoxybenzyl), Aloc(allyloxy-carbonyl), Fmoc (9-fluorenylmethoxycarbonyl) and Boc(t-butyloxycarbonyl). Following reaction with the coupling agent, theprotecting group may be removed by cleavage of the protecting groupunder mild acid conditions, for example in the presence of a solution oftrifluoracetic acid (TFA).

During backbone cyclization of peptide, the peptide at the C-terminal ofthe linear peptide is exposed to an activating group of the couplingagent and as the reaction proceeds a keto-enol intermediate is producedat the alpha carbon of this amino acid. The enol (or alkenol)intermediate can therefore lead to the production of two enantiomerswhen the activating group is removed from the adjacent carbon and apeptide bond is formed. This racemization i.e. the formation of therespective enantiomers of the individual amino acid (for exampledextrorotatory and levorotatory forms (i.e. d and l isomersrespectively)) and production of diastereomers of the peptide as awhole, can occur at the site of cyclisation upon activation by thecoupling agent used. Since it is desirable for the peptides of theinvention to be enantiomerically pure, production of undesirablediastereomers should be reduced or prevented. In order to reduce orprevent this production of diastereomers, and produce adiastereometrically pure peptide, the peptide of the invention may bemodified to include an achiral moiety that prevents racemization of thepeptide during cyclisation.

Thus in a further preferred aspect of the invention the peptide of theinvention, or the peptide defined in the process of the invention, ismodified to include a moiety that prevents the formation of peptidediastereomers during cyclisation. As used herein a “racemic peptide” isone that contains quantities (typically equal quantities) of therespective optical isomers, for example dextrorotatory and levorotatoryforms (i.e. d and l isomers respectively), of the amino acid at theC-terminal of the peptide prior to cyclisation of the peptide. Themoiety introduced into the peptide is generally an achiral amino acidwhich may be a naturally occurring amino acid or an amino acid analogue.The achiral amino acid may be selected from the group consisting ofglycine, β-alanine, 3-aminopropanoic acid, 4-amino butyric acid,5-aminopentanoic acid and 6-aminohexanoic acid. In one embodiment of theinvention the peptide is modified at the C-terminal to include anachiral amino acid, for example glycine.

As well as modifying the peptide of the invention to include a moiety,as defined herein, at the C-terminal, the ratio of the two enantiomersformed during cyclisation of the peptide is dependent on several factorssuch as the solvent used, incubation time and temperature duringcyclization (i.e. reaction with the coupling agent) and the activatinggroup used to facilitate the cyclisation.

The present invention further relates to cyclized peptides obtainable bythe process of the invention.

In one embodiment of the invention, the cyclic peptide comprises anamino acid sequence selected from the group consisting of:

K-K-K-K-K-K-K;

R-R-R-R-R-R-R;

O-O-O-O-O-O-O;

DR-DR-DR-DR-DR-DR-DR;

DO-DO-DO-DO-DO-DO-DO; and

DK-DK-DK-DK-DK-DK-DK.

To identify active peptides that have little or no undesired toxicityfor mammalian cells, individual peptides, or libraries of peptides, canbe made and the individual peptides or peptides from those libraries canbe screened for antimicrobial activity and toxicity, including, but notlimited to, antifungal, antibacterial, antiviral, antiprotozoal,anti-parasitic activity and toxicity.

The peptides of the invention can exist in different forms, such as freeacids, free bases, esters and other prodrugs, salts and tautomers, forexample, and the invention includes all variant forms of the compounds.

Thus, the invention encompasses the salt or pro-drug of a peptide orpeptide variant of the invention.

The peptide of the invention may be administered in the form of apharmaceutically acceptable salt. The pharmaceutically acceptable saltsof the present invention can be synthesized from the parent peptidewhich contains a basic or acidic moiety by conventional chemicalmethods. Generally, such salts can be prepared by reacting the free acidor base forms of the peptide with a stoichiometric amount of theappropriate base or acid in water or in an organic solvent, or in amixture of the two; generally, nonaqueous media like ether, ethylacetate, ethanol, isopropanol, or acetonitrile are preferred. Lists ofsuitable salts are found in Remington's Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, Pa., US, 1985, p. 1418, thedisclosure of which is hereby incorporated by reference; see also Stahlet al, Eds, “Handbook of Pharmaceutical Salts Properties Selection andUse”, Verlag Helvetica Chimica Acta and Wiley-VCH, 2002.

The invention thus includes pharmaceutically-acceptable salts of thepeptide of the invention wherein the parent compound is modified bymaking acid or base salts thereof for example the conventional non-toxicsalts or the quaternary ammonium salts which are formed, e.g., frominorganic or organic acids or bases. Examples of such acid additionsalts include acetate, adipate, alginate, aspartate, benzoate,benzenesulfonate, bisulfate, butyrate, citrate, camphorate,camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate,ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate,hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.Base salts include ammonium salts, alkali metal salts such as sodium andpotassium salts, alkaline earth metal salts such as calcium andmagnesium salts, salts with organic bases such as dicyclohexylaminesalts, N-methyl-D-glutamine, and salts with amino acids such asarginine, lysine, and so forth. Also, the basic nitrogen-containinggroups may be quaternized with such agents as lower alkyl halides, suchas methyl, ethyl, propyl, and butyl chloride, bromides and iodides;dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates,long chain halides such as decyl, lauryl, myristyl and stearylchlorides, bromides and iodides, aralkyl halides like benzyl andphenethyl bromides and others.

Salts of carboxyl groups of a peptide or peptide variant of theinvention may be prepared in the usual manner by contacting the peptidewith one or more equivalents of a desired base such as, for example, ametallic hydroxide base, e.g. sodium hydroxide; a metal carbonate orbicarbonate such as, for example, sodium carbonate or bicarbonate; or anamine base such as, for example, triethylamine, triethanolamine and thelike.

The invention includes prodrugs for the active pharmaceutical species ofthe described peptide, for example in which one or more functionalgroups are protected or derivatized but can be converted in vivo to thefunctional group, as in the case of esters of carboxylic acidsconvertible in vivo to the free acid, or in the case of protectedamines, to the free amino group. The term “prodrug,” as used herein,represents in particular structures which are rapidly transformed invivo to the parent structure, for example, by hydrolysis in blood.

A further aspect of the invention provides a pharmaceutical compositioncomprising a pharmaceutically effective amount of a peptide of theinvention, or two or more different peptides of the invention.

The composition also includes a pharmaceutically acceptable carrier,excipient or diluent. The phrase “pharmaceutically acceptable” isemployed herein to refer to those compounds, materials, compositions,and/or dosage forms which are, within the scope of sound medicaljudgment, suitable for use in contact with the tissues of human beingsor, as the case may be, an animal without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The peptide of the invention is useful, inter alia, as an antimicrobialpeptide, for example, against bacteria, fungi, yeast, parasites,protozoa and viruses. The term, “antimicrobial peptide” can be usedherein to define any peptide that has microbicidal and/or microbistaticactivity and encompasses, non-exclusively, any peptide described ashaving anti-bacterial, anti-fungal, anti-mycotic, anti-parasitic,anti-protozoal, anti-viral, anti-infectious, anti-infective and/orgermicidal, algicidal, amoebicidal, microbicidal, bacterici(o)dal,fungicidal, parasiticidal, protozoacidal, protozoicidal properties.

In a preferred aspect, the invention provides the use of a peptideaccording to the invention in the manufacture of a medicament fortreating a microbial infection.

By “microbial infection” is meant an infection caused by a bacterium,parasite, protozoa, virus or fungus including yeast. A “pathogen” isgenerally defined as any disease-causing organism.

A bacterial pathogen may be derived from a bacterial species selectedfrom the group, but not exclusive to the group, consisting of:Staphylococcus spp., e.g. Staphylococcus aureus (e.g. Staphylococcusaureus NCTC 10442 and Staphylococcus aureus ATCC25923), Staphylococcusepidermidis; Chlamydia spp., e.g. Chlamydia trachomatis, Chlamydiapneumoniae, Chlamydia psittaci; Enterococcus spp., e.g. Enterococcusfaecalis; Streptococcus pyogenes; Listeria spp.; Pseudomonas spp.;Mycobacterium spp., e.g. Mycobacterium tuberculosis; Enterobacter spp.;Campylobacter spp.; Salmonella spp.; Streptococcus spp., e.g.Streptococcus Group A or B, Streptoccocus pneumoniae; Helicobacter spp.,e.g. Helicobacter pylori; Neisseria spp., e.g. Neisseria gonorrhoea,Neisseria meningitidis; Borrelia burgdorferi; Shigella spp., e.g.Shigella flexneri; Escherichia coli (E. coli O157:H7 NCTC 12900);Haemophilus spp., e.g. Haemophilus influenzae; Francisella tularensis;Bacillus spp., e.g. Bacillus anthracis; Clostridia spp., e.g.Clostridium botulinum, Clostridium difficile; Yersinia spp., e.g.Yersinia pestis; Treponema spp.; Burkholderia spp., e.g. Burkholderiacepacia, B. mallei, B pseudomallei; and Propionibacterium spp., e.g. P.acnes.

In a preferred use according to the invention the bacterial pathogen isStaphyloccus aureus or E. coli.

A viral pathogen may be derived from a virus selected from, but notlimited to, the group consisting of: Human Immunodeficiency Virus (HIV1& 2); Human T Cell Leukaemia Virus (HTLV 1 & 2); Ebola virus; humanpapilloma virus (e.g. HPV-2, HPV-5, HPV-8 HPV-16, HPV-18, HPV-31,HPV-33, HPV-52, HPV-54 and HPV-56); papovavirus; rhinovirus; poliovirus;herpesvirus; adenovirus; Epstein Barr virus; influenza virus; hepatitisB and C viruses; Variola virus; rotavirus; and SARS coronavirus.

A parasitic pathogen may be derived from a parasite selected from, butnot limited to, the group consisting of Trypanosoma spp. (Trypanosomacruzi, Trypansosoma brucei), Leishmania spp., Giardia spp., Trichomonasspp., Entamoeba spp., Naegleria spp., Acanthamoeba spp., Schistosomaspp., Plasmodium spp., Crytosporidium spp., Isospora spp., Balantidiumspp., Loa Loa, Ascaris lumbricoides, Dirofilaria immitis, and Toxoplasmassp., e.g. Toxoplasma gondii.

In a preferred use according to the invention the microbial infection isa fungal infection.

A fungal pathogen may be derived from a fungus (including yeast)selected from, but not limited to, the genera Candida spp., (e.g. C.albicans), Epidermophyton spp., Exophiala spp., Microsporum spp.,Trichophyton spp., (e.g. T. rubrum and T. interdigitale), Tinea spp.,Aspergillus spp., Blastomyces spp., Blastoschizomyces spp., Coccidioidesspp., Cryptococcus spp. (e.g. Cryptococcus neoformans), Histoplasmaspp., Paracoccidiomyces spp., Sporotrix spp., Absidia spp.,Cladophialophora spp., Fonsecaea spp., Phialophora spp., Lacazia spp.,Arthrographis spp., Acremonium spp., Actinomadura spp., Apophysomycesspp., Emmonsia spp., Basidiobolus spp., Beauveria spp., Chrysosporiumspp., Conidiobolus spp., Cunninghamella spp., Fusarium spp., Geotrichumspp., Graphium spp., Leptosphaeria spp., Malassezia spp. (e.g MalasseziaFurfur), Mucor spp., Neotestudina spp., Nocardia spp., Nocardiopsisspp., Paecilomyces spp., Phoma spp., Piedraia spp., Pneumocystis spp.,Pseudallescheria spp., Pyrenochaeta spp., Rhizomucor spp., Rhizopusspp., Rhodotorula spp., Saccharomyces spp., Scedosporium spp.,Scopulariopsis spp., Sporobolomyces spp., Syncephalastrum spp.,Trichoderma spp., Trichosporon spp., Ulocladium spp., Ustilago spp.,Verticillium spp., and Wangiella spp.

In a preferred use according to the invention the fungal pathogen is ofthe genera Trichophyton spp. or Cryptococcus spp. For example the fungalpathogen may be Trichophyton rubrum, Trichophyton interdigitale orCryptococcus neoformans.

The fungal infection may be a systemic, topical, subcutaneous, cutaneousor mucosal infection.

Topical fungal infections of the nails and skin are generally caused bydermatophytes although some non-dermatophytes such as yeast can alsocause skin infections. The dermatophyte infection may include a Tineainfection for example Tinea barbae (beard), Tinea capitis (head), Tineacorporis (body), Tinea cruris (groin), Tinea faciei (face), Tinea manuum(hand), Tinea pedis (foot) Tinea unguium (nail), Tinea (Pityriasis)versicolor, Tinea incognito or Tinea nigra. The infection may be derivedfrom fungi of the genera Epidermophyton, Microsporum or Trichophytonspp. (e.g. T. rubrum and T. interdigitale).

The dermatophytic infection may be an infection of the skin, lamina,stratum corneum, nails (fingernails and toenails) or hair. Of particularmention are dermatophytic infections caused by a dermatophyte of thegenera Trichophyton, Epidermophyton or Microsporum. Exemplarydermatophytes include Epidermophyton floccosum, Microsporum canis,Microsporum audouinii, Microsporum gypseum, Microsporum nanum,Microsporum ferrugineum, Microsporum distortum, Microsporum fulvum,Trichophyton rubrum, Trichophyton mentagrophytes var. interdigitale,Trichophyton mentagrophytes var. nodulare, Trichophyton tonsurans,Trichophyton soudanese, Trichophyton violaceum, Trichophyton megnini,Trichophyton schoenlenii, Trichophyton gallinae, Trichophyton krajdenii,Trichophyton yaoundei, Trichophyton equinum, Trichophyton erinacei andTrichophyton verrucosum.

In a particular embodiment of the invention, the dermatophytic infectionis onychomycosis. The term “onychomycosis” includes, but is not limitedto, distal lateral subungual, superficial white, proximal whitesubungual, secondary dystrophic, primary dystrophic, endonyx, candidal(e.g. onycholysis & chronic mucocutaneous disease) types ofonychomycosis and Tinea ungium.

Non-dermatophytic fungi associated with onychomycosis includeAspergillus spp. Cephalosporum spp., Fusarium oxysporum, Scopularisbrevicaulis, and Scytalidium spp.

The peptides of the invention are potent antimicrobial peptides for awide variety of pathogenic organisms. However, the peptides of theinvention may also be useful in the treatment of other conditionsincluding, but not limited to, conditions associated with mucosalinfections, for example, cystic fibrosis, gastrointestinal, urogenital,urinary (e.g kidney infection or cystitis) or respiratory infections.

The peptides of the invention may also be useful in the treatment orprevention of infections associated, typically with skin, including,inter alia, wounds, ulcers and lesions for example, cutaneous woundssuch cuts or burns, and conditions associated therewith.

In a preferred aspect of the invention the peptides are useful in thetreatment of bacterial skin infections or “pyodermas”.

The term “treatment” relates to the effects of the peptides describedherein that impart a benefit to patients afflicted with an (infectious)disease, including an improvement in the condition of the patient ordelay in disease progression.

As used herein “treatment of a wound” may include wound healing andassociated conditions and therapy which promotes, augments, oraccelerates healing of tissues and includes post-operative scarring,burns, ulcers, psoriasis, acceleration of tissue remodeling, forexample, post cosmetic surgery and organ transplantation.

Thus, in a further aspect of the invention there is provided a substrateto which a peptide of the invention is applied or attached. Preferably,the substrate is suitable for application to wounds or delivery to woundsites. Preferably, the substrate allows for the transfer of the peptidesof the invention from the substrate to a wound bed to achieve theirantibiotic effect. The substrate may be a dressing, for example, wounddressing. The dressing may comprise a fabric material or it may be acollagen-like material.

The peptides of the invention may also find application as/in adisinfectant. In this context, the peptide or pharmaceuticalcompositions of the invention may be applied, either alone or incombination with other disinfecting agents, to a surface to be treated.As used herein a “surface to be treated” may be a substrate as definedherein or a medical device.

In a further aspect, the invention provides a method of treating orpreventing a microbial infection in a subject comprising administeringto said subject a therapeutically effective amount of a peptideaccording to the invention.

In a preferred method of the invention, the microbial infection is afungal infection. In the method of the invention the peptide is appliedtopically to the skin or nails of said subject.

Mammals, birds and other animals may be treated by the peptides,compositions or methods described herein. Such mammals and birds includehumans, dogs, cats and livestock, such as horses, cattle, sheep, goats,chickens and turkeys and the like. Moreover, plants may also be treatedby the peptides, compositions or methods of the invention.

Where the subject is an animal, the method of the invention may beapplied to nail-like features, including, but not exclusive to, hooves,claws and trotters.

The method of the invention may include, in addition to peptidetreatment, treatments that enhance peptide permeation into the nail.This could be facilitated by chemical or physical means. Physicaltreatments, such as nail etching or filing of the dorsal layer of thenail may enhance permeability of the peptides of the invention. Chemicalenhancement of nail permeability to the peptides of the invention may beachieved by breaking physical or chemical bonds within the nail platekeratin. Nail softening agents, including, but not exclusive to, ureaand salicylic acid, increase hydration of the nail to decrease naildensity and, therefore, may increase permeability to the peptides of theinvention. Compounds containing sulfhydryl groups will cleave thedisulfide bonds in nail keratin, and may lead to destabilization andincreased permeability of drugs.

In a further aspect, the invention provides a method of treating a woundin a subject comprising applying to the wound a therapeuticallyeffective amount of a peptide, or a substrate, according to theinvention.

To achieve the desired effect(s), the peptide, a variant thereof or acombination thereof, may be administered as single or divided dosages,for example, of at least about 0.01 mg/kg to about 500 to 750 mg/kg, ofat least about 0.01 mg/kg to about 300 to 500 mg/kg, at least about 0.1mg/kg to about 100 to 300 mg/kg or at least about 1 mg/kg to about 50 to100 mg/kg of body weight or at least about 1 mg/kg to about 20 mg/kg ofbody weight, although other dosages may provide beneficial results. Theamount administered will vary depending on various factors including,but not limited to, the peptide chosen and its clinical effects, thedisease, the weight, the physical condition, the health, the age of themammal, whether prevention or treatment is to be achieved, and if thepeptide is chemically modified.

Administration of the therapeutic agents in accordance with the presentinvention may be in a single dose, in multiple doses, in a continuous orintermittent manner, depending, for example, upon the recipient'sphysiological condition, whether the purpose of the administration istherapeutic or prophylactic, and other factors known to skilledpractitioners. The administration of the peptides of the invention maybe essentially continuous over a pre-selected period of time or may bein a series of spaced doses. Both local and systemic administration iscontemplated.

To prepare the composition, peptides are synthesized or otherwiseobtained, purified as necessary or desired, and then lyophilized andstabilized. The peptide can then be adjusted to the appropriateconcentration and optionally combined with other agents. The absoluteweight of a given peptide included in a unit dose can vary widely. Forexample, about 0.01 to about 2 g or about 0.01 to about 500 mg, of atleast one peptide of the invention, or a plurality of peptides specificfor a particular cell type can be administered. Alternatively, the unitdosage can vary from about 0.01 g to about 50 g, from about 0.01 g toabout 35 g, from about 0.1 g to about 25 g, from about 0.5 g to about 12g, from about 0.5 g to about 8 g, from about 0.5 g to about 4 g, or fromabout 0.5 g to about 2 g.

Thus, one or more suitable unit dosage forms comprising the therapeuticpeptides of the invention can be administered by a variety of routesincluding oral, parenteral (including subcutaneous, intravenous,intramuscular and intraperitoneal), rectal, dermal, transdermal,intrathoracic, intrapulmonary and intranasal (respiratory) routes. Thetherapeutic peptides may also be formulated in a lipid formulation orfor sustained release (for example, using microencapsulation, see WO94/07529, and U.S. Pat. No. 4,962,091). The formulations may, whereappropriate, be conveniently presented in discrete unit dosage forms andmay be prepared by any of the methods well-known to the pharmaceuticalarts. Such methods may include the step of mixing the therapeutic agentwith liquid carriers, solid matrices, semi-solid carriers, finelydivided solid carriers or combinations thereof, and then, if necessary,introducing or shaping the product into the desired delivery system.

When the therapeutic peptides of the invention are prepared for oraladministration, they are generally combined with a pharmaceuticallyacceptable carrier, diluent or excipient to form a pharmaceuticalformulation, or unit dosage form. For oral administration, the peptidesmay be present in a powder, a granular formation, a solution, asuspension, an emulsion or in a natural or synthetic polymer or resinfor ingestion of the active ingredients from a chewing gum. The activepeptides may also be presented as a bolus, electuary or paste. Orallyadministered therapeutic peptides of the invention can also beformulated for sustained release, e.g., the peptides can be coated,micro-encapsulated, or otherwise placed within a sustained deliverydevice. The total active ingredients in such formulations comprise from0.1 to 99.9% by weight of the formulation.

Pharmaceutical formulations containing the therapeutic peptides of theinvention can be prepared by procedures known in the art usingwell-known and readily available ingredients. For example, the peptidecan be formulated with common excipients, diluents, or carriers, andformed into tablets, capsules, solutions, suspensions, powders, aerosolsand the like. Examples of excipients, diluents, and carriers that aresuitable for such formulations include buffers, as well as fillers andextenders such as starch, cellulose, sugars, mannitol, and silicicderivatives. Binding agents can also be included such as carboxymethylcellulose, hydroxymethylcellulose, hydroxypropyl methylcellulose andother cellulose derivatives, alginates, gelatine, andpolyvinyl-pyrrolidone. Moisturizing agents can be included such asglycerol, disintegrating agents such as calcium carbonate and sodiumbicarbonate. Agents for retarding dissolution can also be included suchas paraffin. Resorption accelerators such as quaternary ammoniumcompounds can also be included. Surface active agents such as cetylalcohol and glycerol monostearate can be included. Adsorptive carrierssuch as kaolin and bentonite can be added. Lubricants such as talc,calcium and magnesium stearate, and solid polyethyl glycols can also beincluded. Preservatives may also be added. The compositions of theinvention can also contain thickening agents such as cellulose and/orcellulose derivatives. They may also contain gums such as xanthan, guaror carbo gum or gum arabic, or alternatively polyethylene glycols,bentones and montmorillonites, and the like.

For example, tablets or caplets containing the peptides of the inventioncan include buffering agents such as calcium carbonate, magnesium oxideand magnesium carbonate. Suitable buffering agents may also includeacetic acid in a salt, citric acid in a salt, boric acid in a salt andphosphoric acid in a salt. Caplets and tablets can also include inactiveingredients such as cellulose, pregelatinized starch, silicon dioxide,hydroxyl propyl methyl cellulose, magnesium stearate, microcrystallinecellulose, starch, talc, titanium dioxide, benzoic acid, citric acid,corn starch, mineral oil, polypropylene glycol, sodium phosphate, zincstearate, and the like. Hard or soft gelatin capsules containing atleast one peptide of the invention can contain inactive ingredients suchas gelatin, microcrystalline cellulose, sodium lauryl sulfate, starch,talc, and titanium dioxide, and the like, as well as liquid vehiclessuch as polyethylene glycols (PEGs) and vegetable oil. Moreover,enteric-coated caplets or tablets containing one or more peptides of theinvention are designed to resist disintegration in the stomach anddissolve in the more neutral to alkaline environment of the duodenum.

The therapeutic peptides of the invention can also be formulated aselixirs or solutions for convenient oral administration or as solutionsappropriate for parenteral administration, for instance byintramuscular, subcutaneous, intraperitoneal or intravenous routes. Thepharmaceutical formulations of the therapeutic peptides of the inventioncan also take the form of an aqueous or anhydrous solution ordispersion, or alternatively the form of an emulsion or suspension orsalve.

Thus, the therapeutic peptides may be formulated for parenteraladministration (e.g. by injection, for example, bolus injection orcontinuous infusion) and may be presented in unit dose form in ampules,pre-filled syringes, small volume infusion containers or in multi-dosecontainers. The active peptides and other ingredients may formsuspensions, solutions, or emulsions in oily or aqueous vehicles, andmay contain formulatory agents such as suspending, stabilizing and/ordispersing agents. Alternatively, the active peptides and otheringredients may be in powder form, obtained by aseptic isolation ofsterile solid or by lyophilization from solution for constitution with asuitable vehicle, e.g., sterile, pyrogen-free water before use.

These formulations can contain pharmaceutically acceptable carriers,vehicles and adjuvants that are well-known in the art. It is possible,for example, to prepare solutions using one or more organic solvent(s)that is/are acceptable from the physiological standpoint, chosen, inaddition to water, from solvents such as acetone, acetic acid, ethanol,isopropyl alcohol, dimethyl sulfoxide, glycol ethers such as theproducts sold under the name “Dowanol”, polyglycols and polyethyleneglycols, C₁-C₄ alkyl esters of short-chain acids, ethyl or isopropyllactate, fatty acid triglycerides such as the products marketed underthe name “Miglyol”, isopropyl mytrisate, animal, mineral and vegetableoils and polysiloxanes.

Solvents or diluents comprising the peptides of the invention mayinclude acid solutions, dimethylsulfone, N-(2-mercaptopropionyl)glycine, 2-n-nonyl-1,3-dioxolane and ethyl alcohol. Preferably thesolvent/diluent is an acidic solvent, for example, acetic acid, citricacid, boric acid, lactic acid, propionic acid, phosphoric acid, benzoicacid, butyric acid, malic acid, malonic acid, oxalic acid, succinic acidor tartaric acid.

Also contemplated are combination products that include one or morepeptides of the present invention and one or more other antimicrobial orantifungal agents, for example, polyenes such as amphotericin B,amphotericin B lipid complex (ABCD), liposomal amphotericin B (L-AMB),and liposomal nystatin, azoles and triazoles such as voriconazole,fluconazole, ketoconazole, itraconazole, pozaconazole and the like;glucan synthase inhibitors such as caspofungin, micafungin (FK463), andV-echinocandin (LY303366); griseofulvin; allylamines such asterbinafine; flucytosine or other antifungal agents, including thosedescribed herein. In addition, it is contemplated that the peptidesmight be combined with topical antifungal agents such as ciclopiroxolamine, haloprogin, tolnaftate, undecylenate, topical nysatin,amorolfine, butenafine, naftifine, terbinafine, and other topicalagents.

Additionally, the peptides may be formulated as sustained release dosageforms and the like. The formulations can be so constituted that theyrelease the active peptide, for example, in a particular part of theintestinal or respiratory tract, possibly over a period of time.Coatings, envelopes, and protective matrices may be made, for example,from polymeric substances, such as polylactide-glycolates, liposomes,microemulsions, microparticles, nanoparticles, or waxes. These coatings,envelopes, and protective matrices are useful to coat indwellingdevices, e.g. stents, catheters, peritoneal dialysis tubing, drainingdevices and the like.

For topical administration, the active agents may be formulated as isknown in the art for direct application to a target area. Forms chieflyconditioned for topical application take the form, for example, ofcreams, milks, gels, powders, dispersion or microemulsions, lotionsthickened to a greater or lesser extent, impregnated pads, ointments orsticks, aerosol formulations (e.g. sprays or foams), soaps, detergents,lotions or cakes of soap. Other conventional forms for this purposeinclude wound dressings, coated bandages or other polymer coverings,ointments, creams, lotions, pastes, jellies, sprays, and aerosols. Thus,the therapeutic peptides of the invention can be delivered via patchesor bandages for dermal administration. Alternatively, the peptide can beformulated to be part of an adhesive polymer, such as polyacrylate oracrylate/vinyl acetate copolymer. For long-term applications it might bedesirable to use microporous and/or breathable backing laminates, sohydration or maceration of the skin can be minimized. The backing layercan be any appropriate thickness that will provide the desiredprotective and support functions. A suitable thickness will generally befrom about 10 to about 200 microns.

Topical administration may be in the form of a nail coating or lacquer.For example, the antifungal peptides can be formulated in a solution fortopical administration that contains ethyl acetate (NF), isopropylalcohol (USP), and butyl monoester of poly[methylvinyl ether/maleicacid] in isopropyl alcohol.

Pharmaceutical formulations for topical administration may comprise, forexample, a physiologically acceptable buffered saline solutioncontaining between about 0.001 mg/ml and about 100 mg/ml, for examplebetween 0.1 mg/ml and 10 mg/ml, of one or more of the peptides of thepresent invention specific for the indication or disease to be treated.

Ointments and creams may, for example, be formulated with an aqueous oroily base with the addition of suitable thickening and/or gellingagents. Lotions may be formulated with an aqueous or oily base and willin general also contain one or more emulsifying agents, stabilizingagents, dispersing agents, suspending agents, thickening agents, orcoloring agents. The active peptides can also be delivered viaiontophoresis, e.g., as disclosed in U.S. Pat. No. 4,140,122; 4,383,529;or 4,051,842. The percentage by weight of a therapeutic agent of theinvention present in a topical formulation will depend on variousfactors, but generally will be from 0.01% to 95% of the total weight ofthe formulation, and typically 0.1-85% by weight.

Drops, such as eye drops or nose drops, may be formulated with one ormore of the therapeutic peptides in an aqueous or non-aqueous base alsocomprising one or more dispersing agents, solubilizing agents orsuspending agents. Liquid sprays can be pumped, or are convenientlydelivered from pressurized packs. Drops can be delivered via a simpleeye dropper-capped bottle, via a plastic bottle adapted to deliverliquid contents drop-wise, or via a specially shaped closure.

The therapeutic peptide may further be formulated for topicaladministration in the mouth or throat. For example, the activeingredients may be formulated as a lozenge further comprising a flavoredbase, usually sucrose and acacia or tragacanth; pastilles comprising thecomposition in an inert base such as gelatin and glycerin or sucrose andacacia; and mouthwashes comprising the composition of the presentinvention in a suitable liquid carrier.

Specific non-limiting examples of the carriers and/or diluents that areuseful in the pharmaceutical formulations of the present inventioninclude water and physiologically acceptable buffered saline solutionssuch as phosphate buffered saline solutions pH 7.0-8.0.

The peptides of the invention can also be administered to therespiratory tract. For administration by inhalation or insufflation, thecomposition may take the form of a dry powder, for example, a powder mixof the therapeutic agent and a suitable powder base such as lactose orstarch. Therapeutic peptides of the present invention can also beadministered in an aqueous solution when administered in an aerosol orinhaled form. Thus, other aerosol pharmaceutical formulations maycomprise, for example, a physiologically acceptable buffered salinesolution containing between about 0.001 mg/ml and about 100 mg/ml forexample between 0.1 and 100 mg/ml, such as 0.5-50 mg/ml, 0.5-20 mg/ml,0.5-10 mg/ml, 0.5-5 mg/ml or 1-5 mg/ml of one or more of the peptides ofthe present invention specific for the indication or disease to betreated.

Throughout the description and claims of this specification, the words“comprise” and “contain” and variations of the words, for example“comprising” and “comprises”, means “including but not limited to”, andis not intended to (and does not) exclude other moieties, additives,components, integers or steps.

Throughout the description and claims of this specification, thesingular encompasses the plural unless the context otherwise requires.In particular, where the indefinite article is used, the specificationis to be understood as contemplating plurality as well as singularity,unless the context requires otherwise.

Features, integers, characteristics, compounds, chemical moieties orgroups described in conjunction with a particular aspect, embodiment orexample of the invention are to be understood to be applicable to anyother aspect, embodiment or example described herein unless incompatibletherewith.

EXAMPLES Materials and Methods Example 1

Cyclization of a 7 amino acid polylysine peptide was performed bydissolving leg of protected peptide with 1 eq (eq=equivalent volume) ofHATU in DMF (dimethylformamide) at 100 mg/ml. To increase the pH 2.5 eqof DIEA (diisopropylethylamine) were added and the progress of thereaction followed by HPLC. When complete the peptide was precipitated inwater and washed in further water. The peptide was then dried andde-protected with hydrofluoric acid in order to produce the final cyclicpeptide. Ion-exchange chromatography is then used to replace thehydrofluoric acid solvent with acetic acid prior to lyophilization.

Example 2

Cyclization of a 7 amino acid polyarginine peptide was performed bycombining leg of protected peptide with 5 eq of NaHCO₃ (sodiumbicarbonate) and 2 eq of PyBOP dissolved in DMF at 28.5 mg/ml. Thereaction was followed by TLC and when complete the peptide wasprecipitated in water and washed in further water. The peptide was thendried and dc-protected with hydrofluoric acid in order to produce thefinal cyclic peptide. Ion-exchange chromatography is then used toreplace the hydrofluoric acid solvent with acetic acid prior tolyophilization.

Example 3 Cyclization of a 7 Amino Acid Polyarginine Peptide

Solution 1: 57 mg of HBTU (Mwt=379.3, 0.15 mmole) or 57 mg of HATU(M=380.3, 0.15 mmole) and 60 μl of 0.92 mg/ml NMM (n-methylmorpholine,Mwt=101.2, 0.55 mmole) were dissolved in 2.86 ml of DMF.

Solution 2: 288 mg of H-[Arg(Pbf)]₇-OH (Mwt=2877.6, 0.1 mmole) (7 aminoacid polyarginine peptide) were dissolved in 0.71 ml of DMF.

Solution 2 was added dropwise to solution 1 over 30 min. The pH waschecked by wet pH paper and must be 8.5-9. The reaction mixture wasstirred at room temperature overnight*. The mixture was concentratedunder vacuum. A solution of NaHCO3 (5%) was added. The precipitate ofprotected cyclopeptide was filtered and washed with water. 150-200 mgwas obtained. The cleavage of Pbf groups were performed in TFA/Water(95/5, v/v) (10 ml for 1 g of protected cyclopeptide). The mixture wasconcentrated and IPE was added to precipitate the crude product. 100-110mg of crude cycloArg was obtained. (*The coupling using HATU wascomplete after 5 hours. Quantity of NMM depend to excess of TFA inH-[Arg(Pbf)]₇-OH.)

The cyclic peptides are synthesized to be at least 95% enantiomericallypure, and tend to vary between 97 and 99%. They are at least 95%enantiomerically pure as synthesized by this method.

Broth Dilution Antifungal Susceptibility Testing

The sensitivity of relevant fungal strains to the cyclized peptides wasdetermined using Clinical Laboratory Standard Institute (CLSI; formerlyNCCLS) Approved Standards. Fungal susceptibility was tested using“Reference Method for Broth Dilution Antifungal Susceptibility Testingof Filamentous Fungi; Approved Standard M38-P”, and yeast susceptibilitywas tested using “Reference Method for Broth Dilution AntifungalSusceptibility Testing of Yeasts; Approved Standard—Second EditionM27-A”.

Broth Dilution Antibacterial Susceptibility Testing

The sensitivity of relevant bacterial strains to the cyclized peptideswas determined using Clinical Laboratory Standard Institute (CLSI;formerly NCCLS) Approved Standards. Bacterial susceptibility was testedusing “Methods for Dilution Antimicrobial Susceptibility Tests forBacteria That Grow Anaerobically; Approved Standard—Seventh EditionM7-A7”

Haemolysis Assays

The peptide under study was aliquoted at the desired concentration intriplicate in Nunc 96 well plates, and serial 1:1 dilutions (100 μl)were made. 100 μl of washed (3 washes of 50 ml HBSS) pooled human redblood cells (RBC) (1×10⁸ RBC/ml) were added to the test wells andincubated at 37° C. for 3 hours. After incubation a further 100 μl ofHBSS was added to all the wells and the plate was incubated at 4° C.overnight. 100 μl of the supernatant was removed and placed in a freshmicrotitre plate which was read in a Sunrise plate reader (Tascam) at450/620 nm. Control wells (quadruplicate) of buffer alone, buffer andRBCs, and H₂O and RBC were also included. The data were plotted andstatistically analyzed using Graph Pad (Prism software).

Results

Sequence of Cyclized Peptides

The sequence of the peptides analyzed is as follows:

Peptide 1: Cyclic-K-K-K-K-K-K-K

Peptide 2: Cyclic-R-R-R-R-R-R-R

Peptide 3: Cyclic-K-K-K-K-K-K-K-G

Peptide 4: Cyclic-R-R-R-R-R-R-R-G

Peptide 5: Cyclic-O-O-O-O-O-O-O-G

Peptide 6: Cyclic-DR-DR-DR-DR-DR-DR-DR-G

Peptide 7: Cyclic-DO-DO-DO-DO-DO-DO-DO-G

Peptide 8: Cyclic-DK-DK-DK-DK-DK-DK-DK-G

The prefix ‘D-’ indicates a D-isomer of the amino acid was used in thesynthesis of the peptide. ‘O’ represents the non-natural amino acidornithine.

Cyclic peptides consisting of 3, 5, 9, 11, 13 or 15 arginine or lysineamino acids have been synthesized and activity has been determined (datanot shown).

Antibacterial Activity of Cyclised Peptides

Cultures of E. coli and Staphylococcus aureus were exposed to Peptide 1and the MIC after growth over the following 16 hours at 37° C. was 1 mMfor both organisms (Table 2). Peptide 1 totally inhibits growth of bothE. coli and Staphylococcus aureus at this concentration.

This experiment was repeated with Peptide 2. The MIC for Peptide 2versus E. coli was 0.1 mM; The MIC for Peptide 2 versus S. aureus was1.0 mM. This indicates a significant impact of the cyclized peptides onbacterial activity.

Linear peptides corresponding in size to peptides 1 and 2 demonstratedsignificantly lower activity than peptides 1 and 2 respectively.

Antifungal Activity of Cyclised Peptides Versus Trichophyton rubrum

T. rubrum susceptibility to peptides 1-8 was tested. Peptide 1demonstrated an MIC of 0.1 mM versus cultures of T. rubrum (Table 2).Peptide 2 demonstrated an MIC of 0.25 mM versus cultures of T. rubrum.

Linear peptides corresponding in size to peptides 1 and 2 demonstratedsignificantly lower activity than peptides 1 and 2 respectively.

Peptides 3-8 had a single glycine residue introduced into the cyclicpeptide ring. Thus, Peptides 3-8 are 8 amino acids in length, comparedto 7 amino acids for Peptides 1-2. Peptides 3-6 all demonstratedantifungal activity against T. rubrum (MIC (mM) 4.0, 2.0, 4.0, 1.0,respectively). Peptides 7-8 did not demonstrate antifungal activityagainst T. rubrum at the maximum concentration tested (4 mM).

Peptides 3-6 demonstrate antifungal activity, but the introduction ofthe non-cationic amino acid glycine significantly reduces antifungalactivity. For example, this can be seen in the activity of Peptide 2 (noGlycine; MIC=0.2 mM) compared with Peptide 4 (Glycine added; MIC=2.0 mM)(Table 2). This data shows that antifungal activity is present in cyclicpeptides of both 7 and 8 amino acids in length, but that peptides ofreduced cationicity are less antifungal towards T. rubrum.

Inhibition of Trichophyton interdigitale by Cyclised Peptides

T. interdigitale susceptibility to peptides 2-8 was tested. Antifungalactivity of Peptides 2-8 against T. interdigitale is shown in Table 2.Peptides 2, 4 and 6 were active towards T. interdigitale.

Inhibition of Cryptococcus neoformans by Cyclised Peptides

C. neoformans susceptibility to peptides 4 and 6-8 was tested using“Reference Method for Broth Dilution Antifungal Susceptibility Testingof Yeasts; Approved Standard—Second Edition M27-A”.

Table 2 demonstrates that cationic cyclic peptides 4 and 6-8 areantifungal versus the pathogenic yeast C. neoformans (MICs=1.0 mM, 0.5mM, 2.0 mM and 0.5 mM, respectively).

Antimicrobial Activity of Peptide 2 Versus Selected Microbial Pathogens

The antimicrobial activity of Peptide 2 against 60 selected microbialpathogens is demonstrated in Table 3. As can be seen, greatestantimicrobial activity (i.e. lowest MICs) is consistently seen againstfungi, especially dermatophytes, Scopulariopsis brevicaulis, Malasseziafurfur, non-albicans Candida spp. and the bacterium E. coli.

Effect of the Use of Enantiomeric Amino Acids in the Cyclized Peptides

Comparison of the inhibitory effect of all-L and all-D cyclic cationicpeptides is demonstrated in Table 2. Peptides 4 and 6 are all-L andall-D equivalent cyclic cationic peptides containing the amino acidsarginine (7 aa) and glycine (1 aa). Antifungal activity against T.rubrum is greater for the all-D version than the all-L version (MIC=1.0and 2.0 mM, respectively). Antifungal activity against T. interdigitaleis greater for the all-D version than the all-L version (MIC=0.25 and0.5 mM, respectively). Antifungal activity against the yeast C.neoformans is greater for the all-D version than the all-L version(MIC=0.5 and 1.0 mM, respectively). This indicates that the all-Dversion of this peptide is more active than the all-L version.

Peptides 3 and 8 are all-L and all-D equivalent cyclic cationic peptidescontaining the amino acids lysine (7 aa) and glycine (1 aa). Antifungalactivity against T. rubrum is greater for the all-L version than theall-D version (MIC=4.0 and >4.0 mM, respectively). Neither peptidedemonstrates antifungal activity against T. interdigitale (MIC>4.0 mMfor both peptides).

Haemolytic Activity of Cyclized Peptides

The haemolytic activities of cyclic cationic peptides (Table 4) arenegligible at concentrations in excess of those demonstrating antifungalactivity.

Hepatotoxicity of Cyclized Peptides

Peptides 2, 9 and 10 show no hepatotoxicity at concentrations similar tothose demonstrating antifungal activity.

TABLE 1 Coupling agents

Uroniumfuminium salts HBTU: R¹ = R² = CH₂; X = CH (N-form structure)HBPyU: R¹, R² = (CH₂)₄; X = CH (unknown) HATU: R¹ = R² = CH₂; X = N(N-form structure) HAPyU: R¹, R² = (CH₂)₄; X = N (N-form structure)

Immunium salts BOMI: R¹ = R² = CH₂, R³ = H; X = CH (N-form structure)BDMP: R¹, R³ = (CH₂)₃, R² = CH₂; X = CH (N-form structure) DPMP: R¹ = R²= (CH₂)₄, R³ = Ph; X = CH (unknown) AOMP: R¹, R² = (CH₂)₃, R³ = CH₃; X =N (unknown)

Phosphonium salts BOP: R¹ = R² = CH₃; X = CH PyBOP: R¹, R² = (CH₂)₄; X =CH AOP: R¹ = R² = CH₃; X = N PyAOP: R¹, R² = (CH₂)₄; X = N

TABLE 2 Antimicrobial Activity (MIC; mM) of Cyclised Peptides versusSelected Microbial Pathogens Molecular Pep- Weight T. T. E. S. C. tide(Da) rubrum interdigitale coli aureus neoformans 1 879.2 0.1 ND 1.0 1.0ND 2 1093.3 0.25 <0.125 0.1 0.25 ND 3 954.3 4.0 >4.0 ND ND ND 4 1150.42.0 0.5 ND ND 1.0 5 856.1 4.0 >4.0 ND ND ND 6 1150.4 1.0 0.25 ND ND 0.57 856.1 >4.0 >4.0 ND ND 2.0 8 954.3 >4.0 >4.0 ND ND 0.5

TABLE 3 Antimicrobial Activity (MIC; mM) of Peptide 2 versus SelectedMicrobial Pathogens MIC MIC Fungus Number (mM) Bacterium Number (mM) T.rubrum NCPF118 0.25 S. aureus ¹ NCTC10442 0.25 T. rubrum 7 Clinical0.5-1.0 S. aureus ³ NCTC6571 >1.9 Isolates² T. interdigitale NCPF335<0.125 S. aureus ² NCTC10788 >1.9 T. mentagrophytes DM2006 978 0.5 S.aureus ² ATCC12598 0.95 T. mentagrophytes DM2006 1023 0.5 S. aureus ²NCTC8325 >1.9 M. furfur DSM6170 0.031 S. aureus ¹ Col 0.95 S.brevicaulis NCPF2177 0.5 S. aureus ¹ N315 0.95 S. brevicaulis DM20061025 0.5 S. aureus ¹ ANS46 0.95 A. niger NCPF2022 0.5 S. aureus ¹ MW20.95 A. terreus NCPF2729 >2 S. aureus 16 Clinical >3.8 Isolates⁴Fusarium NCPF2722 >2 Ps. aeruginosa ATCC27853 >1.9 oxysporum Fusariumspp DM2006 294 >2 Ps. aeruginosa DSM50071 >2 Fusarium spp DM2006 495 >2Ps. aeruginosa ATCC27853 >2 Fusarium spp DM2006 1026 >2 B. cepaciaATCC25609 >1.9 C. albicans NCTC3179 >2 E. coli NCTC12900 0.1 C. albicansATCC24433 >2 S. aureus ATCC25923 >0.1 C. albicans ATCC90028 >2 P. acnesDSMZ1897 0.125 C. albicans AM2003-020 >2 S. epidermidis ATCC12228 0.025C. albicans IHEM3742 >2 C. difficile NCTC11209 >2 C. albicanss20122.073 >2 E. coli No strain 0.1 designation C. krusei NCPT39530.128-0.256 S. aureus No strain 0.25 designation C. krusei ATCC62580.125 C. parapsilosis ATCC22019 0.25 C. parapsilosis ATCC90018 1.0 ¹MRSA(Methicillin-resistant S. aureus) ²Reference Numbers: DM2006 517; DM2006902; DM2006 932; DM2006 953; DM2006 1008; DM2006 1093; DM2006 1377 ³MSSA(Methicillin-sensitive S. aureus) ⁴Reference Numbers: 97.2935.K;98.1695.K; 97.2637.D; 98.2028.X; 05.5240.R; 00.9523.R; 03.8996.T;98.1515.F; 00.5472.R; 00.1039.P; 02.6225.E; 03.3200.J; 01.7995.S;03.8951.G; 00.9521.M; 97.1636.D

TABLE 4 Haemolytic Activity of Selected Peptides versus Red Blood CellsMaximum Concentration Tested Peptide (mM) Haemolysis 1 2 73.7 None 310.0 None 4 10.0 None 5 10.0 None 6 5.0 None 7 10.0 None 8 10.0 None

The invention claimed is:
 1. A topical pharmaceutical compositioncomprising a cyclic peptide and a pharmaceutically acceptable carrier,excipient or diluent; wherein the cyclic peptide comprises from 5 to 13contiguous arginine residues.
 2. The topical pharmaceutical compositionof claim 1, wherein the cyclic peptide comprises 7 contiguous arginineresidues.
 3. The cyclic peptide of claim 2, wherein the arginineresidues are D-amino acids.
 4. The cyclic peptide of claim 2, whereinthe arginine residues are L-amino acids.
 5. A composition consistingessentially of a cyclic peptide and a pharmaceutically acceptablecarrier, excipient or diluent; wherein the cyclic peptide comprises from5 to 13 contiguous arginine residues.
 6. The composition of claim 5,wherein the cyclic peptide comprises 7 contiguous arginine residues. 7.The cyclic peptide of claim 6, wherein the arginine residues are D-aminoacids.
 8. The cyclic peptide of claim 6, wherein the arginine residuesare L-amino acids.